Sign in
TerminatedNo phase

Investigating Orthobiologics After PRP and Photobiomodulation for Knee Osteoarthritis

Key facts

Who runs it
Musculoskeletal Injury Rehabilitation Research for Operational Readiness
Where
Tacoma, United StatesSee the site
Trial code
Status
Terminated
People taking part
33 people enrolled
Started
13 Oct 2023
Ended
10 Oct 2024
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Physical Therapy
  • Platelet-Rich Plasma Injection
  • Photobiomodulation Therapy
Record updated
8 November 2024
Why it stopped
The Institutional Review Board terminated the protocol on 10 October 2024.

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 33 criteriaShow less

Who can take part

  • DEERS Eligible
  • Between 18-64 (Inclusive)
  • Civilian
  • Contractor
  • Active Duty Service Member
  • Knee Osteoarthritis diagnosis; at least 3 of the following:; >50 years old; Morning stiffness < 30 minutes; Crepitus on active movements; Tenderness of the bony margins of the joint; Bony enlargement; No palpable warmth
  • Fluent in speaking and reading English
  • Ability to commit to study intervention and follow-up
  • Willing to avoid prohibited treatments while enrolled in the study (NSAIDs/COX-2 inhibitors and ASAs for 5 days prior to and 2 weeks following study injection or beginning of treatment, and oral steroids, steroid injections, and viscos supplementation)
  • Radiographic evidence of knee osteoarthritis as assessed by Kellgren-Lawrence grade 1 or higher

Who cannot take part

  • Previous enrollment for contralateral knee
  • Hx of arthroscopic surgery on the study knee within the past year
  • Received dry needling within the past 4 weeks
  • Received prolotherapy (e.g. CSI or PRP injection), within past month
  • Current use of medications associated with sensitivity to heat or light (e.g., amiodarone, chlorpromazine, doxycycline, hydrochlorothiazide, nalidixic acid, naproxen, piroxicam, tetracycline, thioridazine, voriconazole)
  • Diagnosis of fibromyalgia or chronic fatigue syndrome
  • Diagnosis of porphyria (light induced allergy) or photosensitive eczema
  • Hx of underlying cardiac disease
  • Diagnosis of autoimmune disease
  • Hx of memory problems, dementia, and/or impaired decision-making ability
  • Any other serious medical conditions(s) that might preclude optimal outcome and/or interfere with participation (e.g.), intra-articular sepsis, bacteremia, fracture, joint instability, rheumatoid arthritis, osteoporosis, cancer, coagulopathy, etc.)
  • Current participation in other research studies for knee OA
  • Hx of arthroplasty on the study knee
  • Recent (within the last 3 months) lower extremity injury (e.g., ankle sprain, meniscus tear or sprain, etc.) that required professional medical attention, and occurred in the ipsilateral extremity of the study knee
  • Confounding, coexisting pathology suspected to be the primary source of their pain [e.g., acute meniscal tear (with mechanical symptoms), ligamentous changes (with clinical instability) or hemarthrosis]
  • Current or chronic sciatica (lumbosacral radiculopathy) resulting in chronic or intermittent lower extremity pain, numbness, or tingling
  • Diagnosis of neuropathy affecting sensation to pain
  • Diagnosis of inflammatory arthropathy
  • Hx of adverse reaction to PRP injection (either documented in the medical record or shared by the patient during screening)
  • Tattoo in treatment area
  • Current use of pacemaker
  • Albinism
  • Current pregnancy or plans to become pregnant during intervention period

Where in United States

  • Madigan Army Medical CenterTacoma, United States

About the trial

What the trial wants to find out

This research assesses the effects that Photobiomodulation Therapy (PBMT) has on Intra-articular administered Plasma-Rich Platelet (PRP) injections for Knee Osteoarthritis (KOA) treatment through evaluations of synovial and serum inflammatory and reparative biomarkers.

Read full original descriptionShow less

A comparison of Physical Therapy (PT) vs PT + PRP vs PT + PBMT vs PT + PRP + PBMT for KOA treatment is made. The relationship between self-reported pain and functionality and treatment mechanisms is analyzed along with an analysis of the intersectionality between participant self-reported pain and functionality and medicine markers across treatment groups. These aims seek to inform current treatment practices in treating KOA and returning Active-Duty Service Members to duty readiness.

The 4 groups in the trial

  • Physical Therapy (PT) OnlyExisting treatment, for comparison

    All participants will complete a standard of care PT program addressing individual strength, mobility, and flexibility deficits in both proximal and distal muscle groups. The provider may also use other modalities to address distal issues. If a participant has not been placed on profile at the time of consent, a profile may be written by the study medical provider to ensure limitation of activities, as appropriate.

    Treatment: Physical Therapy

  • PT + Platelet-Rich Plasma (PRP)Existing treatment, for comparison

    PRP Preparation: The PRP will be prepared following standard technique by drawing 60cc blood from the participant through venipuncture and spinning the blood sample in a centrifuge (for approximately 17 minutes), adjusting for leukocyte poor-platelet rich plasma (LP-PRP). This sample will be prepared by the study provider. Any leftover blood will be safely discarded per standard protocols. A small portion of the pre-spin whole blood (approximately 1 cc) and post-spin injectant PRP (approximately 1 cc) will be sent to MAMC Department of Pathology and Laboratory Services (DPALS) for complete blood count (CBC) cytology to monitor standardization and reproducibility. This portion will be labeled by participant ID and study. De-identified hardcopy results will be obtained from MAMC DPALS, and CBC results will be reported on Appendix G (CBC Results CRF). Post-procedural instructions will be provided in a participant handout.

    Treatment: Physical Therapy and Platelet-Rich Plasma Injection

  • PT + Photobiomodulation Treatment (PBMT)Existing treatment, for comparison

    In addition to SOC PT, the PBMT group will receive PBM treatment, as outlined below. PBM treatments will occur 3 times each week, for 3 weeks. A member of the study team will measure the treatment area according to a standard protocol and calculate the treatment time (approximately 5-20 minutes). PBMT will be delivered at 6 J/cm2 and 25W and applied in a serpentine pattern to the knee area. Participants will be asked to refrain from using perfumes or plant extracts (e.g., St. John's Wort) in the treatment area(s), as this can increase skin photosensitivity.

    Treatment: Physical Therapy and Photobiomodulation Therapy

  • PT + PRP + PBMTExisting treatment, for comparison

    In addition to SOC PT, the PRP and PBMT group will receive PRP treatment and PBMT treatments. Participants in this group will start PBMT treatments on the same day after receiving the study PRP injection. On the day of the PRP injection, the participant will be instructed to rest for 5-10 minutes prior to the PBMT application and team member will ensure the participant is comfortable not in pain. Immediately following the study injection, the team member will take care not to provide the PBMT over the injected area; however, all subsequent PBMT treatments will be delivered to the knee where the PRP was injected.

    Treatment: Physical Therapy, Platelet-Rich Plasma Injection, and Photobiomodulation Therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Investigating Orthobiologics After Platelet-Rich Plasma and Photobiomodulation Treatment of Knee Osteoarthritis
Record updated
8 November 2024